-
1ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatmentby Kowalski, D.M., Reinmuth, N., Orlov, S.V., Fischer, J.R., Sugawara, S., Mandziuk, S., Medine, D.M., Novello, S., Takeda, Y., Soo, R.A., Park, K., McCleod, M., Geater, S.L., Powell, M., May, R., Stockman, P., Planchard, D.Get access
Published in Annals of Oncology (2018)
Get access
Get access
Get access
Article in Journal/Newspaper